STOCK TITAN

Kazia Therapeutics Limited American Depositary Shares - $KZIA STOCK NEWS

Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: $KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kazia Therapeutics American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kazia Therapeutics American Depositary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.34%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
Kazia Therapeutics Limited American Depositary Shares

Nasdaq:KZIA

KZIA Rankings

KZIA Stock Data

7.45M
219.00M
18.54%
0.98%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW SOUTH WALES 2113

About KZIA

innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi